Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11528 posts found.

roche__tree

Roche’s Tecentriq combo outclasses Nexavar in unresectable hepatocellular carcinoma

November 25, 2019 Research and Development, Sales and Marketing Cancer, Roche, immunotherapy, pharma, tecentriq

Roche has revealed new Phase 3 data for its immunotherapy drug Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) in the …
News
uk

Scotland leading the UK in life science start-up growth, report reveals

November 20, 2019 Research and Development, Sales and Marketing BioCity, UK, biotech, pharma

A new report published by the life science incubator and business collective BioCity has painted a promising picture of UK …
News
merck-keytruda

Europe approves Keytruda for first-line head and neck squamous cell carcinoma, as a monotherapy or combo

November 20, 2019 Research and Development, Sales and Marketing Cancer, keytruda, pharma

MSD’s top-selling immunotherapy Keytruda (pembrolizumab) has secured another approval from the European Commission, this time in the first-line treatment of …
News
darzalex-product-shot---100mg-vial-2-hr

European Commission approves Genmab’s Darzalex combo in newly diagnosed multiple myeloma

November 20, 2019 Research and Development, Sales and Marketing Europe, Genmab, darzalex, pharma

Genmab’s Darzalex (daratumumab) has secured approval from the European Commission and is now authorised in Europe for the treatment of …
News
shutterstock_138095450

Keytruda overtakes Opdivo to lead sales in global immune checkpoint inhibitor market, report reveals

November 19, 2019 Manufacturing and Production, Sales and Marketing Bristol-Myers Squibb, MSD, keytruda, opdivo, pharma

MSD’s Keytruda (pembrolizumab) overtook Bristol-Myers Squibb’s (BMS) blockbuster drug Opdivo (nivolumab) in total sales in the third quarter of 2019 …
News
alk_logo_32_nodith

Alkermes snaps up Rodin Therapeutics for a potential $950 million

November 19, 2019 Manufacturing and Production, Sales and Marketing Alkermes, Rodin Therapeutics, pharma

Dublin’s Alkermes is set to acquire US firm Rodin Therapeutics in a deal worth a potential $950 million, it has …
News
capture

Bringing the clinical trial home

November 18, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing clinical trials, feature, research

Clinical trials are the backbone of healthcare and drug research, but many key patient populations have in the past been …
Feature

Pfizer’s Humira biosimilar secures FDA approval, due to launch in 2023

November 18, 2019 Sales and Marketing Abrilada, FDA, Humira, Pfizer, biosimilar, pharma

Pfizer has confirmed the FDA approval of Abrilada (adalimumab-afzb),  its biosimilar version of AbbVie’s Humira, the world’s best-selling drug,   …
News
mayzent

EMA advisory panel recommends Mayzent for secondary progressive multiple sclerosis

November 18, 2019 Sales and Marketing Europe, Mayzent, Novartis, multiple sclerosis, pharma

Novartis has revealed that Mayzent (siponimod) has been recommended by the European Medicines Agency’s (EMA) Committee for Medicinal Products for …
News
shutter

resTORbio shuts down Phase 3 trial in clinically symptomatic respiratory illness

November 18, 2019 Research and Development, Sales and Marketing pharma, resTORbio

US firm resTORbio has revealed its intention to terminate a Phase 3 trial of its oral, selective TORC1 inhibitor RTB101 …
News
jazz_pharma

Jazz Pharma sleep disorder drug secures CHMP backing for treatment of excessive daytime sleepiness in Europe

November 18, 2019 Research and Development, Sales and Marketing EMA, jazz pharma, narcolepsy, pharma, solriamfetol

Jazz Pharma’s solriamfetol has secured a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human …
News

Novartis’ Adakveo becomes first FDA-approved P-selectin inhibitor for sickle cell disease

November 18, 2019 Sales and Marketing Adakve, Novartis, pharma, sickle cell disease

The FDA has chosen to award Novartis’ Adakveo (crizanlizumab) with marketing authorisation, it has emerged, as a treatment to reduce …
News

Shionogi gains US approval in complicated urinary tract infections with Fetroja

November 15, 2019 Medical Communications, Sales and Marketing FDA, Fetroja, Shiogoni

Shionogi’s antibacterial therapy Fetroja (cefiderocol) has secured approval in the US for the treatment of complicated urinary tract infections (cUTI), …
News
fda2outsideweb

Label expansion of Amarin’s Vascepa has unanimous backing of FDA advisory panel

November 15, 2019 Medical Communications, Sales and Marketing Amarin, FDA, vascepa

The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) has voted in favour of expanding the existing approval of Irish …
News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

November 15, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

As we close in on the weekend, it’s been a week characterised by data reveals and crucial marketing approvals, including …
News
The Gateway to Local Adoption Series

Latest content

NICE recommends daratumumab quadruplet for newly diagnosed multiple myeloma

October 8, 2026

AstraZeneca’s Trixeo approved in EU for asthma

October 8, 2026

Amplio reports early human data for novel methotrexate approach in rheumatoid arthritis

October 7, 2026

Survodutide delivers up to 13.1% weight loss in phase 3 obesity and diabetes trial

October 6, 2026

ESTEVE CDMO adds $17.5m to Illinois expansion

October 6, 2026